gallopamil has been researched along with ketanserin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
| Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S | 1 |
| Belyakov, S; Dambrova, M; Kazoka, H; Kuznecovs, J; Lebedev, A; Liepinsh, E; Mishnev, A; Orlova, N; Ponomaryov, Y; Vavers, E; Veinberg, G; Vikainis, S; Vilskersts, R; Vorona, M; Zvejniece, L | 1 |
| Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
| Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
| Affolter, H; Burkard, WP; Pletscher, A | 1 |
| Kirchengast, M; Lehmann, HD; Rübsamen, K | 1 |
| Allegra, A; Aloisi, C; Baldari, S; Buemi, M; Imbesi, D; Laganà, A; Morabito, N; Palella, S; Privitera, M; Villari, C | 1 |
1 trial(s) available for gallopamil and ketanserin
| Article | Year |
|---|---|
Is erythropoietin-induced hypertension a phenomenon due to the intracellular Ca++ mobilisation?
Topics: Adult; Blood Circulation; Calcium; Erythropoietin; Gallopamil; Humans; Ketanserin; Male; Nifedipine; Recombinant Proteins; Vasoconstrictor Agents; Verapamil | 1994 |
9 other study(ies) available for gallopamil and ketanserin
| Article | Year |
|---|---|
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Topics: Acetamides; Allosteric Regulation; Animals; Rats; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Stereoisomerism; Structure-Activity Relationship | 2013 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets.
Topics: Adenosine Diphosphate; Binding, Competitive; Blood Platelets; Cerebral Cortex; Gallopamil; Humans; In Vitro Techniques; Ketanserin; Membranes; Piperidines; Receptors, Serotonin; Spiperone; Verapamil | 1985 |
Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage.
Topics: Animals; Calcium; Coronary Circulation; Coronary Thrombosis; Dogs; Female; Gallopamil; Hemodynamics; Injections, Intravenous; Ketanserin; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Serotonin Antagonists; Verapamil | 1993 |